{"id":"placebo-to-ozanimod","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Bradycardia (dose-dependent)"}]},"_chembl":{"chemblId":"CHEMBL3707247","moleculeType":"Small molecule","molecularWeight":"404.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ozanimod selectively binds to S1P1 and S1P5 receptors on lymphocytes and other immune cells, preventing their migration from lymph nodes into peripheral circulation. This reduces the number of pathogenic lymphocytes available to infiltrate inflamed tissues. The drug is particularly effective in autoimmune and inflammatory conditions where lymphocyte trafficking drives disease pathology.","oneSentence":"Ozanimod is a selective sphingosine-1-phosphate (S1P) receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing circulating lymphocytes and inflammatory cell infiltration into affected tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:48.124Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT06408259","phase":"PHASE3","title":"Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-04-08","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":194},{"nctId":"NCT03440372","phase":"PHASE3","title":"Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease","status":"TERMINATED","sponsor":"Celgene","startDate":"2018-02-27","conditions":"Crohn Disease","enrollment":625},{"nctId":"NCT03915769","phase":"PHASE3","title":"To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Celgene","startDate":"2019-06-03","conditions":"Colitis, Ulcerative","enrollment":198},{"nctId":"NCT03464097","phase":"PHASE3","title":"A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease","status":"TERMINATED","sponsor":"Celgene","startDate":"2018-06-27","conditions":"Crohn Disease","enrollment":550},{"nctId":"NCT05644665","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2022-12-09","conditions":"Ulcerative Colitis","enrollment":131},{"nctId":"NCT03440385","phase":"PHASE3","title":"Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-03-07","conditions":"Crohn Disease","enrollment":606},{"nctId":"NCT04978298","phase":"PHASE1","title":"Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-07-19","conditions":"Healthy Volunteers","enrollment":128},{"nctId":"NCT02435992","phase":"PHASE3","title":"Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-06-17","conditions":"Ulcerative Colitis","enrollment":1012},{"nctId":"NCT01647516","phase":"PHASE2","title":"Efficacy and Safety Study of Ozanimod in Ulcerative Colitis","status":"COMPLETED","sponsor":"Celgene","startDate":"2012-12-26","conditions":"Ulcerative Colitis","enrollment":199},{"nctId":"NCT01628393","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Celgene","startDate":"2012-09-18","conditions":"Relapsing Multiple Sclerosis","enrollment":258},{"nctId":"NCT02047734","phase":"PHASE3","title":"Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-12-03","conditions":"Relapsing Multiple Sclerosis","enrollment":1320},{"nctId":"NCT02294058","phase":"PHASE3","title":"Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-12-03","conditions":"Multiple Sclerosis","enrollment":1346},{"nctId":"NCT03694119","phase":"PHASE1","title":"Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-07-24","conditions":"Healthy Volunteer","enrollment":92},{"nctId":"NCT03644576","phase":"PHASE1","title":"Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-07-11","conditions":"Healthy Volunteers","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":57,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to ozanimod","genericName":"Placebo to ozanimod","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ozanimod is a selective sphingosine-1-phosphate (S1P) receptor modulator that reduces lymphocyte egress from lymphoid tissues, decreasing circulating lymphocytes and inflammatory cell infiltration into affected tissues. Used for Ulcerative colitis, Crohn's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}